Texplore and I-APC Partner to Develop ExCene Technology

• 举报此文章

DataM Intelligence

DataM Intelligence

Market Research & Consulting Firm. This page updates readers with industry particular reports uploaded on our website.

发布日期: 2024年8月26日

+ 关注

要查看或添加评论，请登录

DataM Intelligence的更多文章

• 2025年3月27日

  UK MHRA Accepts Application for Proposed Biosimilar to Xolair?

  Kashiv BioSciences LLC and ADVANZ PHARMA have announced that the UK Medicines and Healthcare Products Regulatory Agency…

  2
• 2025年3月26日

  FDA Grants Priority Review for Apitegromab’s BLA; EMA Accepts MAA for Spinal Muscular Atrophy Treatment

  In a significant development for the spinal muscular atrophy (SMA) community, Scholar Rock, announced that both the U.S.

  1
• 2025年3月25日

  Syneron Bio Announces Strategic Collaboration with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases

  Syneron Bio, has announced a strategic collaboration with global biopharmaceutical leader AstraZeneca. This partnership…

  2
• 2025年3月24日

  Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S.

  Clearmind Medicine Inc. has announced a significant milestone in the development of its innovative drug candidate…

  2
• 2025年3月21日

  TREMFYA? (guselkumab) FDA Approval: A Breakthrough for Crohn's Disease Treatment

  Johnson & Johnson's TREMFYA? Becomes First and Only IL-23 Inhibitor with Both Subcutaneous and Intravenous Induction…

  2

  1 条评论
• 2025年3月20日

  Pharmaceutical News: Nexus Pharmaceuticals Launches Tranexamic Acid

  Nexus Pharmaceuticals has announced the launch of Tranexamic Acid, marking an important milestone in the company’s…

  1
• 2025年3月18日

  AstraZeneca to Acquire EsoBiotec, Advancing Cell Therapy Capabilities

  AstraZeneca Expands Cell Therapy Pipeline with Acquisition of EsoBiotec AstraZeneca has announced a definitive…

  7
• 2025年3月17日

  ANI Pharmaceuticals Announces FDA Approval for Expanded ILUVIEN? Label

  ANI Pharmaceuticals, Inc. has officially announced that the U.

  2
• 2025年3月13日

  Celltrion Announces U.S. Launch of STEQEYMA? (Ustekinumab-stba), a Biosimilar to STELARA?

  Celltrion has officially launched STEQEYMA? (ustekinumab-stba) in the United States following approval by the U.S.

  1
• 2025年3月11日

  Bristol Myers Squibb to Acquire 2seventy bio

  2seventy bio Announces Acquisition by Bristol Myers Squibb In a strategic move set to enhance its gene therapy and…

  1

Show more

See all articles